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Background:  Patients with resistant hypertension (HTN) are at high risk to have abnormal cardiac structure and function. Mechanisms other than 
blood pressure (BP) may be responsible. Although Baroreflex Activation Therapy® (BAT) has been shown to be efficacious in reducing BP, the long-
term benefit on cardiac structure and function in a large cohort of resistant hypertensive patients has not been fully elucidated.
Methods:  Patients implanted with the Rheos® system had Stage II HTN (systolic BP ≥160 mmHg) and were taking ≥3 anti-HTN drugs including at 
least one diuretic. BAT was activated 1 month after implant. Echo data were analyzed at a blinded core lab. Changes at follow-up vs activation were 
analyzed with paired t-tests.
Results:  12 month data is available on 46 subjects (29 M/17 F, Age 57±11 yr) implanted at 10 centers. BAT improved cardiac structure and 
function while reducing BP. The reduced Mitral A wave velocity coupled with reduced left atrial area and left ventricular mass suggest improved 
diastolic filling and/or reduced end-diastolic pressure. LVMI category improved from 44% reference range, 39% mild/moderately abnormal, and 17% 
severely abnormal at activation to 74% reference range, 20% mild/moderately abnormal, and 6% severely abnormal at 12 months. No unanticipated 
adverse events were reported.
Conclusions:  In addition to sustained BP reduction, chronic BAT reverses left ventricular and left atrial remodeling while improving cardiac 
function.
Activation
(N = 46)
Δ 1 Year
(N = 46)
Left Ventricular Mass Index (g/m2.7) 117.7 ± 4.3 -17.8 ± 3.0†
Left Ventricular Mass (g) 260.2 ± 11.9 -37.3 ± 6.9†
Septal Wall Thickness (mm) 13.3 ± 0.4 -1.1 ± 0.3†
LV Posterior Wall Thickness (mm) 13.0 ± 0.3 -1.3 ± 0.2†
Mitral A wave velocity (m/sec) 0.86 ± 0.03 -0.05 ± 0.03
Mitral E wave velocity (m/sec) 0.82 ± 0.03 -0.03 ± 0.02
Ejection Fraction (%) 69.2 ± 1.1 1.8 ± 1.2
Office Cuff Systolic BP (mmHg) 163.3 ± 3.7 -19.0 ± 5.4*
Office Cuff Diastolic BP (mmHg) 96.9 ± 2.2 -9.0 ± 3.0*
Values: mean ± SEM °p<0.05 *p≤0.01 †p≤0.001
